Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

Brief summary (registry, in English)

The purpose of this study is to determine whether nivolumab is better than ipilimumab to prevent recurrence of melanoma.

What you commit to

• Study type: Interventional · Phase 3
• Participants enrolled: 906
• From 16 Mar 2015 to the primary completion date, 26 Nov 2018
• 136 sites in 25 countries
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 15 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (136)

Sites in registry order. Pick your city on the disease page to sort them by distance.